Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialists.
作者信息
Bangs Rick
机构信息
Bladder Cancer Advocacy Network, Pittsford, New York, USA.
出版信息
BMJ Oncol. 2024 Jun 13;3(1):e000429. doi: 10.1136/bmjonc-2024-000429. eCollection 2024.
Abstract
摘要
相似文献
1
Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialists.应对癌症的隐匿毒性：对临床医生、研究人员和临床试验人员的行动呼吁。
BMJ Oncol. 2024 Jun 13;3(1):e000429. doi: 10.1136/bmjonc-2024-000429. eCollection 2024.
2
Supportive care for patients undergoing immunotherapy.免疫治疗患者的支持性护理。
Support Care Cancer. 2017 Oct;25(10):3017-3030. doi: 10.1007/s00520-017-3802-9. Epub 2017 Jul 13.
3
Dermatologic toxicities related to cancer immunotherapy.与癌症免疫治疗相关的皮肤毒性
Toxicol Rep. 2025 Apr 5;14:102021. doi: 10.1016/j.toxrep.2025.102021. eCollection 2025 Jun.
4
Racism in Palliative Care Research: We Still have a Ways to Go.姑息治疗研究中的种族主义：我们仍有很长的路要走。
J Pain Symptom Manage. 2023 Jan;65(1):1-5. doi: 10.1016/j.jpainsymman.2022.09.009. Epub 2022 Oct 2.
5
Race Roundtable Series: Structural Racism in Palliative Care.种族圆桌系列：姑息治疗中的结构性种族主义
J Pain Symptom Manage. 2022 May;63(5):e455-e459. doi: 10.1016/j.jpainsymman.2022.01.015. Epub 2022 Feb 11.
6
Immunotherapy toxicities in genito-urinary cancers: insights and challenges for clinicians.泌尿生殖系统癌症中的免疫治疗毒性：临床医生的见解与挑战
Curr Opin Urol. 2025 Jul 1;35(4):461-466. doi: 10.1097/MOU.0000000000001295. Epub 2025 May 2.
7
COMPare: Qualitative analysis of researchers' responses to critical correspondence on a cohort of 58 misreported trials.比较：对研究人员针对58项报告有误的试验队列中的批评性通信所作回应的定性分析。
Trials. 2019 Feb 14;20(1):124. doi: 10.1186/s13063-019-3172-3.
8
A clinical decision support tool to predict survival in cancer patients beyond 120 days after palliative chemotherapy.一种临床决策支持工具，用于预测接受姑息性化疗 120 天后癌症患者的生存情况。
J Palliat Med. 2012 Aug;15(8):863-9. doi: 10.1089/jpm.2011.0417. Epub 2012 Jun 12.
9
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.在一项2期癌症治疗试验期间，与临床研究人员共享患者报告的症状毒性和体能状态的可行性及临床影响。
Clin Trials. 2016 Jun;13(3):331-7. doi: 10.1177/1740774515615540. Epub 2015 Nov 4.
10
Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician.免疫检查点抑制剂毒性综述：姑息治疗临床医生的视角
J Pain Symptom Manage. 2018 Sep;56(3):460-472. doi: 10.1016/j.jpainsymman.2018.05.015. Epub 2018 May 22.
引用本文的文献
1
The Burden of Treatment: Experiences of Patients Who Have Undergone Radiotherapy and Proton Beam Therapy.治疗负担：接受放射治疗和质子束治疗患者的经历
Healthcare (Basel). 2025 Jun 5;13(11):1351. doi: 10.3390/healthcare13111351.
本文引用的文献
1
Interventions addressing health-related social needs among patients with cancer.针对癌症患者健康相关社会需求的干预措施。
J Natl Cancer Inst. 2024 Apr 5;116(4):497-505. doi: 10.1093/jnci/djad269.
2
Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer.无症状或毒性的质量调整时间（Q-TWiST）：患者报告结局还是数学模型？癌症领域的系统评价
Psychooncology. 2015 Mar;24(3):253-61. doi: 10.1002/pon.3595. Epub 2014 Jun 11.
Zotero 插件